Asymmetric siRNA Duplex Design for RNAi Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNAi technologies face challenges in achieving specificity and efficacy due to the equal contribution of both siRNA strands to RISC assembly, leading to unintended target silencing.
Innovation Solution
The discovery that siRNA strands can be functionally asymmetric, with only one strand participating in RNAi, allows for the design of siRNA duplexes where the 5' end base pairing determines strand participation, enhancing specificity and efficacy by promoting the entry of the desired strand into the RISC complex while discouraging the sense strand.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If both siRNA strands are allowed to contribute equally to RISC assembly, then the RNAi reaction can proceed with both strands potentially active, but this leads to off-target silencing and reduced specificity
Solution Approach 1:
The patent applies asymmetry by designing siRNA duplexes with unequal base pairing stability at the 5' ends of the two strands. Specifically, the 5' end of the sense strand is designed to have weaker base pairing (lower stability) compared to the 5' end of the antisense strand. This asymmetric design creates a thermodynamic bias that preferentially promotes loading of the antisense strand into RISC while discouraging loading of the sense strand, thereby achieving strand-specific silencing and improving specificity
Solution Approach 2:
The patent changes the thermodynamic parameter (base pairing stability) at specific positions (5' ends) of the siRNA strands. By modifying the sequence composition to create differential stability - with the sense strand 5' end having lower stability than the antisense strand 5' end - the system achieves selective strand loading into RISC. This parameter change transforms a symmetric, non-specific system into an asymmetric, specific system
2Reliability
If the sense strand is discouraged from entering RISC through asymmetric base pairing design, then off-target silencing is reduced, but the design complexity of the siRNA duplex increases
Solution Approach 1:
The patent modifies sequence parameters (nucleotide composition) at the 5' ends of the siRNA strands to create differential base pairing stability. The sense strand 5' end is designed with parameters that result in weaker pairing (lower GC content or intentional mismatches), while the antisense strand 5' end has parameters for stronger pairing. This parameter modification is integrated into the standard siRNA design process, making it a routine consideration rather than adding substantial manufacturing complexity
Solution Approach 2:
The asymmetric base pairing design allows the siRNA duplex to self-select which strand loads into RISC based on thermodynamic principles. The system uses its own internal structure (differential stability at 5' ends) to automatically discriminate between sense and antisense strands during RISC loading, eliminating the need for external intervention or complex additional mechanisms to achieve strand specificity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach improves the specificity and efficacy of RNAi by ensuring that only the intended strand mediates target RNA cleavage, reducing off-target silencing and enhancing the overall efficiency of the RNAi reaction.
Implementation Method 1
the base pair strength between the 5' end of the sense strand and the 3' end of the antisense strand is less than the base pair strength between the 5' end of the antisense strand and the 3' end of the sense strand
Data Source
AI summary
The present invention provides methods of enhancing the efficacy and specificity of RNA silencing. The invention also provides compositions for mediating RNA silencing. In particular, the invention provides siRNAs, siRNA-like molecules, shRNAs, vectors and transgenes having improved specificity and efficacy in mediating silencing of a target gene. Therapeutic methods are also featured.